Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects

Mol Cancer. 2023 Dec 2;22(1):194. doi: 10.1186/s12943-023-01899-4.

Abstract

The molecules of Major histocompatibility class I (MHC-I) load peptides and present them on the cell surface, which provided the immune system with the signal to detect and eliminate the infected or cancerous cells. In the context of cancer, owing to the crucial immune-regulatory roles played by MHC-I molecules, the abnormal modulation of MHC-I expression and function could be hijacked by tumor cells to escape the immune surveillance and attack, thereby promoting tumoral progression and impairing the efficacy of cancer immunotherapy. Here we reviewed and discussed the recent studies and discoveries related to the MHC-I molecules and their multidirectional functions in the development of cancer, mainly focusing on the interactions between MHC-I and the multiple participators in the tumor microenvironment and highlighting the significance of targeting MHC-I for optimizing the efficacy of cancer immunotherapy and a deeper understanding of the dynamic nature and functioning mechanism of MHC-I in cancer.

Keywords: Antigen presentation; B2M; Cancer immune evasion; Cancer immunotherapy; MHC-I; TME.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Membrane / metabolism
  • Histocompatibility Antigens Class I* / genetics
  • Histocompatibility Antigens Class I* / metabolism
  • Humans
  • Immunotherapy
  • Neoplasms* / genetics
  • Neoplasms* / therapy
  • Tumor Microenvironment

Substances

  • Histocompatibility Antigens Class I